XENOLITH

Xenolith Medical develops innovative medical solutions to enhance patient outcomes in minimally invasive procedures, focusing on advanced surgical instruments that improve precision and safety in orthopedics and neurosurgery. Founded in 2010 in Qiryat Gat, Israel, Xenolith Medical specializes in advanced medical technologies. The company secured its first funding round in January 2011, receiving ILS 3. 7 million from Virginia Life Science Investments and Xenia Venture Capital.

Xenolith has completed a total of 1 deal to date, raising a total of ILS 3. 7 million in funding. Xenolith Medical specializes in innovative medical solutions aimed at improving patient outcomes in minimally invasive procedures. The core product offerings include advanced surgical instruments and devices that enhance the precision and safety of operations, specifically in the fields of orthopedics and neurosurgery.

These products are designed to reduce recovery times and improve overall surgical efficacy by integrating advanced technology that facilitates real-time imaging and feedback during procedures. The company targets hospitals, surgical centers, and healthcare providers across North America and Europe, catering to a client base that includes both large healthcare systems and smaller specialty practices. By addressing critical challenges in surgical environments, Xenolith Medical positions itself as a key player in the evolving landscape of medical technology. Xenolith Medical generates revenue primarily through direct sales to healthcare institutions, establishing partnerships with hospital networks to distribute their specialized medical devices.

The company operates on a B2B model, where healthcare providers purchase equipment and instruments to enhance their surgical capabilities. Revenue transactions are structured around bulk purchasing agreements and ongoing service contracts for equipment maintenance and training. Specific pricing plans for flagship products, including proprietary surgical instruments, are tailored to the needs of institutional buyers, reflecting the unique value and technology embedded in each product. This transactional approach fosters long-term relationships with clients and ensures that healthcare providers receive consistent support and access to the latest advancements in medical technology.

Xenolith Medical's strategy for future growth includes the development of new products aimed at enhancing surgical efficiency, with plans to launch these innovations in the coming years. The company is targeting expansion into new markets, specifically in the Asia-Pacific region and Latin America, by 2024. The funding secured in January 2011 will support these initiatives, allowing Xenolith to further invest in product development and market entry strategies.